O'Byrne Jason 4
4 · Vir Biotechnology, Inc. · Filed Nov 18, 2024
Insider Transaction Report
Form 4
O'Byrne Jason
EVP & Chief Financial Officer
Transactions
- Award
Common Stock
2024-11-15+75,000→ 75,000 total - Award
Stock Option (Right to Buy)
2024-11-15+150,000→ 150,000 totalExercise: $8.64Exp: 2034-11-14→ Common Stock (150,000 underlying)
Footnotes (2)
- [F1]Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
- [F2]25% of the shares subject to the stock option vest and become exercisable on November 15, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.